先兆子痫被描述为一种危险且不可预测的妊娠并发症；它会导致孕妇血压突然飙升，并可迅速进展为器官衰竭和死亡。现有治疗主要局限于尽快分娩，通常是紧急剖宫产，而当胎龄在32周及以下——美国每年约有20,000例这样的分娩——时，婴儿的存活和健康发育前景明显下降。

4月27日，由拉维·塔达尼（Ravi Thadhani）和阿南特·卡鲁曼奇（Ananth Karumanchi）在洛杉矶塞达斯-辛奈医学中心（Cedars-Sinai）领导的国际团队在《Nature Medicine》报道了初步结果，显示一种新的方法可能有效。该方法通过过滤母亲血液去除一种有害蛋白，并且似乎能够安全地减缓疾病进展。

尽管结果令人鼓舞，研究仍是仅含16名女性的小规模验证性试验，因此它只是证明了可行性而非临床确证。要明确疗效并支持常规应用，需要规模更大的对照研究，因为在这些高危情况下，哪怕妊娠延长一小段时间，也可能带来婴儿存活和发育方面的巨大收益。

Preeclampsia is described as a dangerous and unpredictable complication of pregnancy; it causes a sudden spike in maternal blood pressure and can rapidly progress to organ failure and death. Existing treatment is mainly limited to rapid delivery, often by emergency C-section, and when delivery occurs at 32 weeks or less, in about 20,000 such U.S. births each year, neonatal survival and healthy development prospects are markedly reduced.

On April 27, an international team led by Ravi Thadhani and Ananth Karumanchi at Cedars-Sinai reported early results in *Nature Medicine* indicating a novel approach may help. The method filters maternal blood to remove a harmful protein and appears to slow disease progression safely.

Despite the encouraging signal, the study was a small proof-of-concept trial involving only 16 women, so it demonstrates feasibility rather than clinical proof. Larger, controlled trials are needed to define efficacy and support routine use, because even a small extension of gestation in these high-risk cases can yield major gains in infant survival and development.

Source: Early days

Subtitle: Blood filtering shows promise as a treatment for pre-eclampsia

Dateline: The Economist May 2nd 2026